ThromboGenics shifts microplasmin priority to deep-vein thrombosis

By Elaine Rigoli

Tampa, Fla., Sept. 26 - ThromboGenics NV said deep-vein thrombosis has become the company's lead development indication for microplasmin in the field of peripheral vascular disease, noting that its commitment to developing microplasmin in vitreoretinal disorders, and for acute stroke as its leading thrombotic indication, remains unchanged.

The Leuven, Belgium-based biotechnology company's decision to change its development priorities in the area of peripheral vascular occlusive disease is due to a number of factors, including the preliminary results from the company's ongoing phase 2a study evaluating microplasmin delivered intra-arterially for the treatment of peripheral arterial occlusive disease.

In parallel with this phase 2a clinical study, ThromboGenics said it reviewed the market opportunity and concluded that deep-vein thrombosis represents both a larger and more attractive opportunity given the positive characteristics of microplasmin.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.